• Diyar Saeed, Christoffer Stark, Wolfgang Otto, Antonio Loforte, Daniel Zimpfer, Alexander M Bernhardt, Evgenij Potapov, Michiel Morshius, David Schibilsky, Alexander Albert, Ayman Raweh, Julia Riebandt, Federico Pappalardo, Matteo Attisani, Mauro Rinaldi, Assad Haneya, Katharina Huenges, Faiz Ramjankhan, Ulrich P Jorde, Daniel Lewin, Khalil Jawad, Hug Aubin, Rafael Ayala, Hermann Reichenspurner, Artur Lichtenberg, Michael Borger, and Jan Gummert.
• Department of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany. Electronic address: diyar.saeed@helios-gesundheit.de.
• J. Thorac. Cardiovasc. Surg. 2024 Aug 1; 168 (2): 569578.e2569-578.e2.

ObjectivesThe Durable Mechanical Circulatory Support System After Extracorporeal Life Support registry is a multicenter registry of patients who were bridged from extracorporeal life support to a durable mechanical circulatory support system. Although numerous studies have highlighted the favorable outcomes after implantation of the HeartMate 3 (Abbott), the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after extracorporeal life support.MethodsData of patients undergoing HeartMate 3 implantation from January 2016 to April 2022 at 14 centers were collected and evaluated. Inclusion criteria were patients with extracorporeal life support before HeartMate 3 implantation. The outcome was reported and compared with patients receiving other types of pumps.ResultsA total of 337 patients were bridged to durable mechanical circulatory support system after extracorporeal life support in the study period. Of those patients, 140 were supported with the HeartMate 3. The other types of pumps included 170 HeartWare HVADs (Medtronic) (86%), 14 HeartMate II devices (7%), and 13 (7%) other pumps (7%). Major postoperative complications included right heart failure requiring temporary right ventricular assist device in 60 patients (47%). Significantly lower postoperative stroke (16% vs 28%, P = .01) and pump thrombosis (3% vs 8%, P = .02) rates were observed in the patients receiving the HeartMate 3. The 30-day, 1-year, and 3-year survivals in patients receiving the HeartMate 3 were 87%, 73%, and 65%, respectively.ConclusionsIn this critically ill patient population, the survivals of patients who were transitioned to the HeartMate 3 are deemed acceptable and superior to those observed when extracorporeal life support was bridged to other types of durable mechanical circulatory support systems.Copyright © 2023 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.

29 keywords...

hide…